...Durezol through its 2011 acquisition of Alcon Inc. , which acquired exclusive, U.S. rights from Sirion Therapeutics Inc....

...Bausch + Lomb Inc. (Rochester, N.Y.) has rights to market Zirgan in the U.S. from Sirion Therapeutics Inc....

...Durezol through its 2011 acquisition of Alcon Inc. , which acquired exclusive, U.S. rights from Sirion Therapeutics Inc....

...Inflammation, Ophthalmic Hired: Todd Creech as CFO and VP of business development, formerly CFO of Sirion Therapeutics Inc....

...the American Academy of Ophthalmology meeting in Chicago next month. ReVision acquired oral fenretinide from Sirion Therapeutics Inc....

...but subsequently said it was revaluating the deal (see BioCentury, April 5, & May 10). Sirion Therapeutics Inc....

...that targets viral DNA. Sirion said Alcon is evaluating the acquisition (see BioCentury, Jan. 25). Sirion Therapeutics Inc....

...gel. Financial terms were not disclosed (see BioCentury Jan. 25). Alcon Inc. (NYSE:ACL), Hunenberg, Switzerland Sirion Therapeutics Inc....

...developing a clinical trial protocol to test the therapeutic potential of fenretinide in acute SCI. Sirion Therapeutics Inc....

...not disclosed. Sirion would not comment on its future plans. Alcon Inc. (NYSE:ACL), Hunenberg, Switzerland Sirion Therapeutics Inc....